TSPAN7 and central nervous system cancer: Furthermore, based on the existing datasets of immunotherapy in GBM, we found that patients with low expression of TSPAN7 and high PD-L1 expression had more response to anti-PD-1 immunotherapy, indicating that anti-PD-1 immunotherapy, combined with over-expressing TSPAN7, could improve the outcomes of glioma.